Citations

Clear

1031 citation(s) found for "Clark, AS".

Digital stress management in cancer: Testing StressProffen in a 12‐month randomized controlled trial
Børøsund, Elin , Ehlers, Shawna L. , Clark, Matthew M. , Andrykowski, Michael A. , Småstuen, Milada Cvancarova, Nes, Lise Solberg , Hagen, Milada , Cvancarova, Milada , Solberg Nes, Lise , Børøsund, Elin

Mayo Clinic

Cancer | December 2, 2021 | Volume: 128 | Issue: 7 | Pages: 1503-1512

10.1002/cncr.34046 | PMID 34855212 Get It

BACKGROUNDCognitive‐behavioral stress management interventions are associated with improved psychological well‐being for cancer survivors. The availability of, access to, and outreach of these in‐person interventions are limited, however. The current study, therefore, evaluated the efficacy of StressProffen, a digital application (app)–based stress management intervention for cancer survivors, in a 12‐month randomized controlled trial.METHODSCancer survivors 1 year or less after their treatment (N = 172) were randomized to the StressProffen intervention (n = 84) or a usual‐care control group (n = 88). The intervention was delivered in a simple blended care model: 1) 1 in‐person introduction session, 2) 10 app‐based cognitive‐behavioral stress management modules, and 3) 2 follow‐up phone calls. Stress (Perceived Stress Scale), anxiety and depression (Hospital Anxiety and Depression Scale), self‐regulatory fatigue (Self‐Regulatory Fatigue 18), and health‐related quality of life (HRQOL; RAND‐36) were examined at the baseline and at 6 and 12 months. Generalized linear models for repeated measures were fitted to compare effects over time.RESULTSParticipants were mainly female (82%), had a mean age of 52 years (standard deviation, 11.3 years; range, 20‐78 years), and had a variety of cancer types (mostly breast cancer [48%]). Over the 12‐month study time, the intervention group reported significantly decreased stress (P < .001), depression (P = .003), and self‐regulatory fatigue (P = .002) as well as improved HRQOL (for 6 of 8 domains, P ≤ .015) in comparison with controls. The largest favored effects for the intervention group were observed at 6 months: stress (estimated mean difference [MD], –5.1; P < .001), anxiety (MD, –1.4; P = .015), depression (MD, –2.1; P < .001), self‐regulatory fatigue (MD, –4.9; P < .001), and HRQOL (7 of 8 domains; P ≤ .037).CONCLUSIONSDigital stress management interventions such as StressProffen have the potential to extend the outreach of psychological interventions and provide easily available and effective psychosocial support for cancer survivors.
The contribution of behavioral features to caregiver burden in FTLD spectrum disorders
Silverman, Hannah , Ake, Jeannie M., Manoochehri, Masood , Brushaber, Danielle , Devick, Katrina L. , Fields, Julie A. , Forsberg, Leah K. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Heuer, Hilary W. , Kornak, John , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Tartaglia, Maria Carmela , Boxer, Adam L. , Rosen, Howard J. , Cosentino, Stephanie , Huey, Edward D. , Barker, Megan S. , Pascual, Belen , Tartaglia, Maria Carmela , Appleby, Brian S. , Dickerson, Bradford Clark , Grossman, Murray , Lapid, Maria I. , Litvan, Irene , Boeve, Bradley F. , Goldman, Jill

Mayo Clinic

Alzheimer's & Dementia | December 2, 2021 | Volume: 18 | Issue: 9 | Pages: 1635-1649

10.1002/alz.12494 | PMID 34854532 Get It

AbstractIntroductionCaregivers of patients with frontotemporal lobar degeneration (FTLD) spectrum disorders experience tremendous burden, which has been associated with the neuropsychiatric and behavioral features of the disorders.MethodsIn a sample of 558 participants with FTLD spectrum disorders, we performed multiple‐variable regressions to identify the behavioral features that were most strongly associated with caregiver burden, as measured by the Zarit Burden Interview, at each stage of disease.ResultsApathy and disinhibition, as rated by both clinicians and caregivers, as well as clinician‐rated psychosis, showed the strongest associations with caregiver burden, a pattern that was consistent when participants were separated cross‐sectionally by disease stage. In addition, behavioral features appeared to contribute most to caregiver burden in patients with early dementia.DiscussionCaregivers should be provided with early education on the management of the behavioral features of FTLD spectrum disorders. Interventions targeting apathy, disinhibition, and psychosis may be most useful to reduce caregiver burden.
Dynamic Aphasia as a Variant of Frontotemporal Dementia
Chandregowda, Adithya, Clark, Heather M., Duffy, Joseph R., Machulda, Mary M., Lowe, Val J., Whitwell, Jennifer L., Josephs, Keith A., Chandregowda, Adithya , Clark, Heather M., Duffy, Joseph R., Machulda, Mary M., Lowe, Val J., Whitwell, Jennifer L., Josephs, Keith A.

Mayo Clinic

Cognitive and Behavioral Neurology | December 1, 2021 | Volume: 34 | Issue: 4 | Pages: 303-318

10.1097/wnn.0000000000000289 | PMID 34851868 Get It

We describe two individuals with progressive verbal difficulty who exhibited impairment of propositional language, with relatively well-preserved auditory comprehension, naming, and repetition—a profile that is consistent with dynamic aphasia. By providing a brief review of pertinent literature and the results from our neurologic, speech and language, neuropsychological, and neuroimaging testing, this report sheds light on the infrequently reported dynamic aphasia in the context of frontotemporal dementia. Our patients’ insights into their verbal difficulty tend to support the notion that dynamic aphasia results from interference at the stage where thoughts are converted into verbal messages—that is, the thought–verbal interface.
A feasibility study of virtual group therapy to improve quality of life of cancer caregivers
Lapid, Maria I. , Atherton, Pamela J., Kung, Simon , Clark, Matthew M. , Sloan, Jeff A. , Whitford, Kevin J. , Gentry, Melanie T. , Miller, Janis J., Rummans, Teresa A. , Hubbard, Joleen M. , Gentry, Melanie T , Lapid, Maria I. , Atherton, Pamela J.

Mayo Clinic

Journal of Psychosocial Oncology | November 29, 2021 | Volume: 40 | Issue: 6 | Pages: 854-867

10.1080/07347332.2021.2000550 | PMID 34842060 Get It

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
Spahn, Ashley, Waldvogel, Stephanie, Howard, Alan , Bar, Merav , Clark, William, Das, Suman Ranjan, Horowitz, Mary M. , Jones, Richard J. , Logan, Brent R. , Riches, Marcie , Sandhu, Karamjeet , Runaas, Lyndsey, Elmariah, Hany , Rezvani, Andrew R. , Bolaños‐Meade, Javier , Saber, Wael , Kean, Leslie S. , Bhatt, Ami S. , Das, Suman R. , Elmariah, Hany , Bhatt, Ami S , Brooks, Erin F. , Howard, Alan, Bratrude, Brandi , Chhabra, Saurabh , Das, Suman Ranjan, Jenq, Robert R. , Levine, John E. , Murthy, Hemant S. , Rashidi, Armin , Riwes, Mary , Sung, Anthony D. , Malki, Monzr M. Al , Gooptu, Mahasweta , Holtan, Shernan G. , Hamadani, Mehdi , Perales, Miguel‐Angel

Mayo Clinic

Blood | November 24, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 2955-2955

10.1182/blood-2021-149313 Get It

Abstract Introduction: The gut microbiome is a potentially modifiable factor in treatment related outcomes in allogeneic hematopoietic cell transplant (HCT). Prior studies have linked pre- or mid-treatment gut microbiome diversity with risk for treatment related morbidity and mortality. However, these studies have been limited by the inclusion of one or only a few institutions and the lack of longitudinal sampling with high quality metadata. These limitations complicate the interpretation of microbiome alterations over the course of HCT. Methods: To overcome these, we devised and implemented a large-scale biospecimen collection protocol in conjunction with BMT CTN 1703, a randomized, multicenter, Phase III trial of tacrolimus/methotrexate vs. post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil in reduced intensity conditioning (RIC) allogeneic HCT (NCT03959241). Patients enrolled on 1703 were optionally co-enrolled in the companion immune and microbiome profiling study, 1801 (MI-IMMUNE). This involved blood, urine and stool sampling before conditioning (PCON), then weekly starting on day 0 through day 77 (through day 84 for blood), and on days 98, 180, 270, 365 and 730. For all enrolled participants where the donor consented, residual donor cells were saved from the empty hematopoietic stem cell product bag for later analysis. Additionally, the protocol included one-time blood, urine and stool sample collection from consented matched related donors (MRDs) prior to stem cell collection. Starting with protocol version 4.0 on February 1, 2021, participation in 1801 stool collection was required for the first six out of eighteen sample collection timepoints. Participation in later stool and urine timepoint collections remained optional. Here we review the feasibility of creating a multi-institutional biobank. Additionally, we assess the success of our strategies by calculating sample collection compliance and standard deviation in compliance across centers for each timepoint. Results: On June 18, 2021, BMT CTN 1703/1801 closed to accrual with 431 patients enrolled on 1703; 323 patients from 36 centers were co-enrolled on 1801. 304 (94%) provided study samples, making this the largest prospective microbiome and immune profiling study in HCT patients to date. As of July 6, 2021, 3,683 blood, 2,668 urine, and 2,098 stool samples had been collected. Across the first 6 timepoints for all participating centers, blood, urine and stool sample collection averaged 93%, 82%, and 74% compliance, respectively. Of the 99 (30%) patients enrolled on 1801 with a MRD, 34 (34%) donors consented to sample collection. Sample collection compliance was lower for MRDs than for patients on the study with 76%, 74%, and 62% of expected blood, urine and stool samples collected, respectively, from this group. For stool collection exclusively, a median of 5 samples were collected per patient across the first 6 timepoints (median of 6 across all timepoints) with 93 (31%) of patients completing a full sample set through Day 28. 139 (46%) patients provided at least one sample after day 28; these represented 37% of the total samples collected to date. The PCON sample, which provides an important measure of pre-treatment gut microbiome diversity, had the third highest compliance with 74% of patients providing a sample. Surprisingly, Day 28 had the lowest compliance (66%) and highest standard deviation (37%) possibly because this timepoint often falls around the time of hospital discharge. Between PCON and day 28, the standard deviation between sites in the average collection compliance (24%) and number of samples collected per patient (1.1) was small indicating the successful adoption of stool collection across institutions. Table 1 summarizes sample collection statistics. Conclusion: Overall this study has resulted in a large, novel biobank of blood, urine and stool samples from patients undergoing RIC allogeneic HCT at 36 centers across the US. This will serve as a valuable resource for investigating the role of the gut microbiome in long term health outcomes following HCT. Although the results of 1801 are forthcoming given ongoing sample collection, the size and composition of the biobank to date clearly demonstrate the feasibility of implementing multi-institutional stool collection. This study represents a critical step towards the large-scale adoption of microbiome sampling as a diagnostic tool. Figure 1 Figure 1. Disclosures Chhabra: GSK: Honoraria. Clark: Kadmon: Consultancy. Horowitz: Mesoblast: Research Funding; Shire: Research Funding; Vertex: Research Funding; Stemcyte: Research Funding; Vor Biopharma: Research Funding; Janssen: Research Funding; Miltenyi Biotech: Research Funding; Kiadis: Research Funding; Sobi: Research Funding; Kite/Gilead: Research Funding; Pfizer, Inc: Research Funding; Jazz Pharmaceuticals: Research Funding; Magenta: Consultancy, Research Funding; Medac: Research Funding; Novartis: Research Funding; GlaxoSmithKline: Research Funding; Daiicho Sankyo: Research Funding; Xenikos: Research Funding; Omeros: Research Funding; Orca Biosystems: Research Funding; Pharmacyclics: Research Funding; Regeneron: Research Funding; Tscan: Research Funding; Takeda: Research Funding; CSL Behring: Research Funding; Genentech: Research Funding; Gamida Cell: Research Funding; Chimerix: Research Funding; Bristol-Myers Squibb: Research Funding; bluebird bio: Research Funding; Astellas: Research Funding; Amgen: Research Funding; Allovir: Consultancy; Actinium: Research Funding; Sanofi: Research Funding; Seattle Genetics: Research Funding. Jenq: Microbiome DX: Consultancy; Merck: Consultancy; Prolacta: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kaleido: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Research Funding; Seres: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; LisCure: Consultancy, Membership on an entity's Board of Directors or advisory committees; MaaT Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Karius: Consultancy. Levine: Equillium Bio: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Research Funding; Kamada: Research Funding; Biogen: Research Funding; Omeros: Membership on an entity's Board of Directors or advisory committees; Symbio: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Talaris Therapeutics: Membership on an entity's Board of Directors or advisory committees; Viracor: Patents & Royalties: GVHD biomarker patent with royalties from Viracor; Mesoblast: Consultancy, Research Funding; X4 Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Murthy: CRISPR Therapeutics: Research Funding. Riches: ATARA Biotherapeutics: Other: Payment; BioIntelect: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Other: Payment. Sung: Merck: Research Funding; Novartis: Research Funding; Enterome: Research Funding; Seres: Research Funding; AVROBIO: Consultancy; Abbott Nutrition: Honoraria; Clasado: Other: Research Product; DSM: Other: Research Product. Al Malki: Neximmune: Consultancy; Jazz Pharmaceuticals, Inc.: Consultancy; Rigel Pharma: Consultancy; Hansa Biopharma: Consultancy; CareDx: Consultancy. Rezvani: Kaleido: Other: One-time scientific advisory board; Nohla Therapeutics: Other: One-time scientific advisory board; Pharmacyclics-Abbvie: Research Funding; US Department of Justice: Consultancy. Bolaños-Meade: Incyte Corp: Consultancy. Holtan: Incyte: Consultancy, Research Funding; Generon: Consultancy. Saber: Govt. COI: Other. Hamadani: Sanofi, Genzyme, AstraZeneca, BeiGene: Speakers Bureau; Janssen, Incyte, ADC Therapeutics, Omeros, Morphosys, Kite: Consultancy; Takeda, Spectrum Pharmaceuticals and Astellas Pharma: Research Funding. Kean: Bluebird Bio: Research Funding; Bristol Myers Squibb: Patents & Royalties: From clinical trial data, Research Funding; Vertex: Consultancy; Novartis: Consultancy; Gilead: Research Funding; Regeneron: Research Funding; EMD Serono: Consultancy. Perales: Cidara: Honoraria; Servier: Honoraria; Incyte: Honoraria, Other; Equilium: Honoraria; Takeda: Honoraria; Novartis: Honoraria, Other; Nektar Therapeutics: Honoraria, Other; NexImmune: Honoraria; MorphoSys: Honoraria; Omeros: Honoraria; Karyopharm: Honoraria; Sellas Life Sciences: Honoraria; Merck: Honoraria; Miltenyi Biotec: Honoraria, Other; Medigene: Honoraria; Bristol-Myers Squibb: Honoraria; Kite/Gilead: Honoraria, Other; Celgene: Honoraria.
NIMG-59. RADIOMICS-PREDICTED T CELL DYNAMICS STRATIFY SURVIVAL AFTER DENDRITIC CELL VACCINE THERAPY FOR PRIMARY GLIOBLASTOMA
Bond, K. Elizabeth, León, Gustavo De , Urcuyo, Javier , Singleton, Kyle , Clark-Swanson, Kamala , Sereduk, Christopher, Hu, Leland , Swanson, Kristin R. , Swanson, Kristin R , Hawkins‐Daarud, Andrea , Leon, Gustavo De, Curtin, Lee , Sereduk, Chris , Tran, Nhan L. , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi142-vi143

10.1093/neuonc/noab196.557 Get It

Abstract INTRODUCTION Dendritic cells (DCs) are potent antigen presenting cells that can be exploited to initiate an adaptive anti-tumoral immune response. DC vaccine clinical trials for primary glioblastoma (GBM) have reported prolonged progression-free survival without any impact on overall survival (OS). We report a radiomics approach that identifies a subpopulation of patients with prolonged OS in clinical trial MC1272. METHODS Twenty adults with primary GBM undergoing standard-of-care therapy were enrolled in MC1272. Autologous DCs were pulsed with allogenic GBM cell lines to generate vaccines that were administered for up to twelve cycles. Standard brain imaging was obtained at the initiation of treatment and two months afterwards. An independent cohort of image-localized biopsies underwent RNA sequencing followed by cellular deconvolution to estimate T cell abundance. A machine learning model was trained to predict intratumoral T cell abundance from imaging features, and the model was applied to MC1272 patient imaging. RESULTS Voxelwise predictions of T cell abundance were generated for each patient’s pre- and post-treatment images. The difference in total intratumoral T cell abundance between imaging timepoints classified patients into increasing or decreasing T cell groups. Patients whose T cells increased had longer OS (median, 21 months) than those whose T cells decreased (median, 10 months; p=0.0035). The significance remained in a Cox proportional hazards analysis that adjusted for patient age and sex (p=0.011). CONCLUSIONS A spatially-resolved radiomics model detected that an intratumoral T cell influx after DC vaccine therapy was associated with prolonged OS. The “post-treatment” imaging in this study was obtained a mere two months after DC vaccine initiation, suggesting that our radiomics model can provide an early indication of treatment responsiveness and prognosis in these patients.
Characterizing Anarthria to Facilitate Neurological Diagnosis: A Case Illustration
Chandregowda, Adithya , Clark, Heather M. , Clark, Heather M

Mayo Clinic

Perspectives of the ASHA Special Interest Groups | October 27, 2021 | Volume: 6 | Issue: 6 | Pages: 1438-1444

10.1044/2021_persp-21-00025 Get It

Purpose: The purpose of this clinical focus article is to illustrate how speech-language pathologist (SLP) characterization of anarthria can contribute to neurological diagnosis and to highlight the challenges associated with such an endeavor. Method: Used in this study are a retrospective chart review and clinicians' experience-based reflections. Results: A 65-year-old man, who, in the context of a neurodegenerative disease, presented with near-complete-loss of speech, was referred by neurologists to SLPs for further characterization of his speech difficulty. Assessment of his limited speech output revealed anarthria with mixed features (spastic and hypokinetic) with superimposed apraxia of speech. Conclusions: SLP characterization of anarthria to facilitate neurological diagnosis is challenging but possible. Clinical lessons learned from this unusual scenario are discussed.
Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids May Extend above and below Pons and Is Associated with Other Autoimmune Diseases
Berry, Brent , Joppa, Stephanie, Labin, Edward, Puram, Vikram , McCleary, Kaci , Clark, H. Brent , Nelson, Flavia , Clark, H Brent

Mayo Clinic

Life | October 22, 2021 | Volume: 11 | Issue: 11 | Pages: 1120

10.3390/life11111120 | PMID 34832996 Get It

Many autoimmune diseases can affect the central nervous system, and their varying clinical presentations often confound a straightforward diagnosis. In this report, we describe a unique presentation of CLIPPERS syndrome. To our knowledge, this is the first case to demonstrate significant supratentorial involvement with symmetric and non-confluent lesions in the medial orbitofrontal cortex; additionally, this is the second case to describe an association between diagnoses of hypothyroidism and CLIPPERS.
Short-Term Lidocaine Infusion as a Nonsedative Option to Maintain Ventilator Synchrony During Opioid Tapering in a COVID-19 Patient
Barman, Ross , Clark, Kathryn J. , Olatoye, Oludare, Clark, Kathryn , Barman, Ross A

Mayo Clinic

Pain Medicine | October 19, 2021 | Volume: 23 | Issue: 3 | Pages: 592-595

10.1093/pm/pnab311 | PMID 34672352 Get It

Autopsy Validation of Progressive Supranuclear Palsy‐Predominant Speech/Language Disorder Criteria
Hokelekli, Fatma Ozlem , Utianski, Rene L. , Ali, Farwa , Stierwalt, Julie A. G., Reichard, R. Ross , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L , Stierwalt, Julie A, Whitwell, Jennifer , Josephs, Keith A , Duffy, Joseph R. , Clark, Heather M. , Botha, Hugo , Machulda, Mary M. , Dickson, Dennis W.

Mayo Clinic

Movement Disorders | October 11, 2021 | Volume: 37 | Issue: 1 | Pages: 213-218

10.1002/mds.28822 | PMID 34632629 Get It

ABSTRACTBackgroundProgressive supranuclear palsy (PSP) may present as a speech/language disorder (PSP‐SL).ObjectiveWe assessed pathological correlates of patients with PSP‐SL who retained the suggestive of PSP‐SL (s.o. PSP‐SL) diagnosis versus those who progressed to possible/probable (poss./prob.) PSP.MethodsThirty‐four prospectively recruited patient with s.o. PSP‐SL completed comprehensive speech/language and neurological assessments longitudinally, died, and underwent autopsy.ResultsTwelve patients (35%) evolved to poss./prob PSP, while 22 (65%) remained as s.o. PSP‐SL. Pathological diagnoses differed across the groups (P = 0.025). Patients with s.o. PSP‐SL had four different neuropathologies (corticobasal degeneration [59%], PSP [13%], Pick's disease [14%], and frontotemporal lobar degeneration with TDP‐43 [14%]), while all patients with poss./prob. PSP had a 4R‐tauopathy (PSP [67%] and corticobasal degeneration [33%]). Development of poss./prob. PSP increased the chance of having PSP pathology by 2.38 times.ConclusionsPSP‐SL is associated with heterogenous pathologies. Evolution of PSP‐SL into poss./prob. PSP is more predictive of underlying PSP pathology than s.o. PSP‐SL. © 2021 International Parkinson and Movement Disorder Society